National Center for Injury Prevention and Control, Initial Review Group, (NCIPC, IRG), 20711 [E9-10292]
Download as PDF
Federal Register / Vol. 74, No. 85 / Tuesday, May 5, 2009 / Notices
2. G Athauda, A Giubellino, JA
Coleman, C Horak, PS Steeg, MJ Lee, J
Trepel, J Wimberly, J Sun, A Coxon, TL
Burgess, DP Bottaro. c-Met ectodomain
shedding rate correlates with malignant
potential. Clin Cancer Res. 2006 Jul
15;12(14 Pt 1):4154–4162.
Patent Status: U.S. Patent Application
No. 11/663,936 filed March 27, 2007
(HHS Reference No. E–257–2004/0–US–
06) and foreign counterparts.
Licensing Status: Available for
licensing.
Licensing Contact: Whitney A.
Hastings; 301–451–7337;
hastingw@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Medical
Oncology Branch, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Targeted Recombinant Adenoviral
Vectors
Description of Technology: The
current invention embodies
recombinant adenoviral vectors for use
in targeted gene transfer. The method by
which these vectors are generated
involves no molecular modifications to
the adenovirus genome, and allows for
the production of vectors targeted
specifically to virtually any cell line of
choice. Specifically, the vectors are
generated by directly linking biotin to
the capsid of adenovirus particles. The
particles are then treated with
streptavidin and subsequently
incubated with a biotinylated targeting
moiety which is capable of recognizing
a specific marker which is expressed on
the surface of selected cells. The
resulting adenoviral vectors are useful
for gene transfer, and can be targeted to
virtually any cell type of interest via
incubation with a specific targeting
moiety.
To date, the inventors have
demonstrated that these vectors can be
specifically directed to target and infect
hematopoietic cell lines which display
the c-kit receptor, and are capable of
achieving high levels of gene expression
in these cell lines. Also, these vectors
can be specifically directed to cell
surface markers such as CD34, CD44
and others through antibodies directly
attached to the biotynilated adenoviral
vectors. Such gene transfer represents a
gene therapy approach upon which the
development of specific therapies
against a broad range of diseases may be
based, including immunodeficiency
VerDate Nov<24>2008
23:12 May 04, 2009
Jkt 217001
20711
diseases, blood cell disorders, and
various cancers.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Applications
Centers for Disease Control and
Prevention
• Adenovirus with gene plus
Biotinylation kit with strepavidin with
ligand or antibody for gene of interest
• Biotin linking kits with methods for
use
Development Status: Delivery of the
biotinylated recombinant adenoviral
vector in vitro for use in targeted gene
transfer.
Inventors: Jonathan Keller et al. (NCI).
Publications
1. JS Smith, JR Keller, NC Lohrey, CS
McCauslin, M Ortiz, K Cowan, SE
Spence. Redirected infection of directly
biotinylated recombinant adenovirus
vectors through cell surface receptors
and antigens. Proc Natl Acad Sci U S A.
1999 Aug 3;96(16):8855–8860.
2. S Ponnazhagan, G Mahendra, S
Kumar, JA Thompson, M Castillas Jr.
Conjugate-based targeting of
recombinant adeno-associated virus
type 2 vectors by using avidin-linked
ligands. J Virol. 2002 Dec;76(24):12900–
12907.
3. M Brandon Parrott, KE Adams, GT
Mercier, H Mok, SK Campos, MA Barry.
Metabolically biotinylated adenovirus
for cell targeting, ligand screening, and
vector purification. Mol Ther. 2003
Oct;8(4):688–700.
Patent Status
• U.S. Patent 6,555,367 issued April
29, 2003 (HHS Reference No. E–193–
1997/0–US–03).
• U.S. Patent Application Publication
No. US2003/0175973, published
September 18, 2003 (HHS Reference No.
E–193–1997/0–US–04).
Licensing Status: Available for
licensing.
Licensing Contact: Whitney A.
Hastings; 301–451–7337;
hastingw@mail.nih.gov.
Dated: April 27, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–10300 Filed 5–4–09; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
National Center for Injury Prevention
and Control, Initial Review Group,
(NCIPC, IRG)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned review group:
Times and Date: 12:30 p.m.–1 p.m., May
20, 2009 (Open). 1 p.m.–3 p.m., May 20, 2009
(Closed).
Place: Teleconference, Toll Free: 888–793–
2154.
Participant Passcode: 4424802.
Status: Portions of the meetings will be
closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and
(6), Title 5, U.S.C., and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Section
10(d) of Public Law 92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services, and the Director, CDC, concerning
the scientific and technical merit of grant and
cooperative agreement applications received
from academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct specific
injury research that focuses on prevention
and control.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of individual research cooperative
agreement applications submitted in
response to Fiscal Year 2009 Requests for
Applications related to the following
individual research announcement: RFA–
EH–09–002 ‘‘Program to Expand State Public
Health Laboratory Capacity for Newborn
Bloodspot Screening (U01)’’.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Jane
Suen, Dr.P.H., M.S., NCIPC, CDC, 4770
Buford Highway, NE., Mailstop F–62,
Atlanta, Georgia 30341, Telephone: (770)
488–4281.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: April 24, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–10292 Filed 5–4–09; 8:45 am]
BILLING CODE 4163–18–P
Frm 00041
Fmt 4703
Sfmt 4703
E:\FR\FM\05MYN1.SGM
05MYN1
Agencies
[Federal Register Volume 74, Number 85 (Tuesday, May 5, 2009)]
[Notices]
[Page 20711]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-10292]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Injury Prevention and Control, Initial Review
Group, (NCIPC, IRG)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
review group:
Times and Date: 12:30 p.m.-1 p.m., May 20, 2009 (Open). 1 p.m.-3
p.m., May 20, 2009 (Closed).
Place: Teleconference, Toll Free: 888-793-2154.
Participant Passcode: 4424802.
Status: Portions of the meetings will be closed to the public in
accordance with provisions set forth in Section 552b(c)(4) and (6),
Title 5, U.S.C., and the Determination of the Director, Management
Analysis and Services Office, CDC, pursuant to Section 10(d) of
Public Law 92-463.
Purpose: This group is charged with providing advice and
guidance to the Secretary, Department of Health and Human Services,
and the Director, CDC, concerning the scientific and technical merit
of grant and cooperative agreement applications received from
academic institutions and other public and private profit and
nonprofit organizations, including State and local government
agencies, to conduct specific injury research that focuses on
prevention and control.
Matters to be Discussed: The meeting will include the review,
discussion, and evaluation of individual research cooperative
agreement applications submitted in response to Fiscal Year 2009
Requests for Applications related to the following individual
research announcement: RFA-EH-09-002 ``Program to Expand State
Public Health Laboratory Capacity for Newborn Bloodspot Screening
(U01)''.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Jane Suen, Dr.P.H., M.S.,
NCIPC, CDC, 4770 Buford Highway, NE., Mailstop F-62, Atlanta,
Georgia 30341, Telephone: (770) 488-4281.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: April 24, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E9-10292 Filed 5-4-09; 8:45 am]
BILLING CODE 4163-18-P